Welcome to Browse Page of Biomarker

This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.

The total number entries retrieved from this search are 452
Please click on Biomarker_ID to view detailed information.
Note: Potential Biomarker with * indicates these signatures are candidate biomarkers extracted from experiments on mice, rat or cell lines and they are not validated on human patients'cohort.
Biomarker IDBiomarkerBiomoleculeSubjectRegulationBiomarker's typeExperimentLevel of significanceSourcePMID
2001ROBO1Protein and RNAsHumanUpregulated (1.5 fold) DiagnosticHCC v/s Normal p < 0.05 (for protein); p < 0.001 (for mRNA)Tissue28977866
2002EZH2RNAsHumanUpregulated (1.5 fold) Diagnostic HCC v/s Normal p < 0.05Tissue28977866
2003GPC3RNAsHumanUpregulated (1.5 fold) DiagnosticHCC v/s Normal p < 0.05Tissue28977866
2004HMMRRNAsHumanUpregulated (1.5 fold) DiagnosticHCC v/s Normal p < 0.05Tissue28977866
2005PLVAPRNAsHumanUpregulated (1.5 fold) DiagnosticHCC v/s Normal p < 0.05Tissue28977866
2006PTTG1RNAsHumanUpregulated (1.5 fold) DiagnosticHCC v/s Normal p < 0.05Tissue28977866
2007TOP2ARNAsHumanUpregulated (1.5 fold) DiagnosticHCC v/s Normal p < 0.05Tissue28977866
2008RACGAP1RNAsHumanUpregulated (1.5 fold) DiagnosticHCC v/s Normal p < 0.05Tissue28977866
2009ASPMRNAsHumanUpregulated (1.5 fold) DiagnosticHCC v/s Normal p < 0.05Tissue28977866
2010CCNB1RNAsHumanUpregulated (1.5 fold) DiagnosticHCC v/s Normal p < 0.05Tissue28977866
2011CDKN3RNAsHumanUpregulated (1.5 fold) DiagnosticHCC v/s Normal p < 0.05Tissue28977866
2012CENPFRNAsHumanUpregulated (1.5 fold) DiagnosticHCC v/s Normal p < 0.05Tissue28977866
2013COL15A1RNAsHumanUpregulated (1.5 fold) DiagnosticHCC v/s Normal p < 0.05Tissue28977866
2014GLUT3ProteinHuman Cell linesEmbryonal HB but not fetal HB tissues express GLUT3 Potential Diagnostic *Embryonal v/s fetal HB (Subtypes of Hepatoblastoma) p < 0.0001Tissue28923827
2015LDHBProteinHuman Cell linesEmbryonal HB but not fetal HB tissues express LDHB proteins Potential Diagnostic *Embryonal v/s fetal HB (Subtypes of Hepatoblastoma) p < 0.01Tissue28923827
2016G6PCProteinHuman Cell linesFetal HBs express G6PC preferentially than embryonal. Potential Diagnostic *Embryonal v/s fetal HB (Subtypes of Hepatoblastoma) p < 0.0001Tissue28923827
2017CERS4RNAsHuman Cell linesUpregulated in HCC Potential Diagnostic *HCC v/s Normal p < 0.001Tissue28789368
2018miR-375miRNAHumanDownregulated in Cancer Diagnostic and PrognosticLiver cancer v/s Normal p < 0.01Tissue28781668
2019miR-221miRNAHumanUpregulated in Cancer Diagnostic and PrognosticLiver cancer v/s Normal p < 0.01Tissue28781668
2021circFUT8circRNAsHumanUpregulated in liver cancer (with fold change 11.44) DiagnosticLiver cancer v/s Normal p < 0.01Tissue28727484
2022circZFRcircRNAsHumanUpregulated in liver cancer (with fold change 13.22) DiagnosticLiver cancer v/s Normal p < 0.001Tissue28727484
2023circIPO11circRNAsHumanUpregulated in liver cancer (with fold change 8.65) DiagnosticLiver cancer v/s Normal p < 0.05Tissue28727484
2024eIF5ProteinHumanUpregulated in chronic hepatitis B (HBV)-associated HCC DiagnosticNormal vs cancer p < 0.001Tissue28715695
2025miR-34a-5pmiRNASprague- Dawley rats Upregulated in TAA-induced hepatocarcinogenesis (with Log fold change more than 1.5 to 4.7) Potential Diagnostic and Prognostic *Control Sprague-Dawley rats and rats treated with TAA at three doses; can predict early HCC p < 0.05Tissue28596526
2026miR-455-3pmiRNASprague- Dawley rats Downregulated in TAA-induced hepatocarcinogenesis Potential Diagnostic and Prognostic *Control Sprague-Dawley rats and rats treated with TAA at three doses; can predict early HCC p < 0.05Tissue28596526
2027HMGB1ProteinHumanUpregulated in HCC PredictiveHCC treated with sorafenib and with HAIC v/s Patients with Pre-treatment. p < 0.05Tissue28474222
2028EMP1-008LncRNAHumanDownregulated in ICC (with log fold change of more than 2) Diagnostic and PrognosticICC v/s Normal; significantly downregulated in ICC with tumor metastasis p < 0.05Tissue28401021
2029ATF3-008LncRNAHumanDownregulated in ICC (with log fold change of more than 2) Diagnostic and PrognosticICC v/s Normal; significantly downregulated in ICC with tumor metastasis p < 0.05Tissue28401021
2030RCOR3-013LncRNAHumanDownregulated in ICC (with log fold change of more than 2) Diagnostic and PrognosticICC v/s Normal; significantly downregulated in ICC with tumor metastasis p < 0.05Tissue28401021
2032miR-9-3RNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2033miR-10bRNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2034miR-31RNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2035miR-519cRNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2036miR-522RNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2037miR-3660RNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2038miR-4784RNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2039miR-6883RNAsHumanUpregulated in the liver cancer cell lines (0.33 fold) PrognosticHBV-HCC v/s Normal; Can predict survival of patients p < 0.05Tissue28322348
2043RKIPProteinHumanDownregulated in liver cancer cell. DiagnosticCancer v/s Normal NATissue28071612
2044lncBRMLncRNAHumanUpregulated in HCC tumours and liver CSCs Diagnostic and PrognosticLiver CSCs (Cancer stem cells) and early and advanced HCC tumours p < 0.001Tissue27905400
2045GABRA3RNAsHumanupregulated in subsets of liver hepatocellular carcinoma (30%) and lung adenocarcinoma (10%) DiagnosticNormal vs cancer p < 0.05Tissue27771326
2046LIN28BRNAsHumanupregulated in subsets of liver hepatocellular carcinoma (30%) and lung adenocarcinoma (10%) DiagnosticNormal vs cancer p < 0.05Tissue27771326
2047MAGEAsRNAsHumanupregulated in subsets of liver hepatocellular carcinoma (30%) and lung adenocarcinoma (10%) DiagnosticNormal vs cancer p < 0.05Tissue27771326
2048RBMYRNAsHumanupregulated in subsets of liver hepatocellular carcinoma (30%) and lung adenocarcinoma (10%) DiagnosticNormal vs cancer p < 0.05Tissue27771326
2049TSPYRNAsHumanupregulated in subsets of liver hepatocellular carcinoma (30%) and lung adenocarcinoma (10%) DiagnosticNormal vs cancer p < 0.05Tissue27771326
2050PKM2ProteinHumanUpregulated in HCC (16 fold) DiagnosticModerately and well differentiated grades v/s poorly differentiated grades of HCC and ICC p < 0.01Tissue27203546
2053CFL1ProteinHuman cell lines and Mice Upregulated in HBV-HCC Diagnostic and PrognosticHBV-HCC vs normal p < 0.05Tissue27708241
2054ADFPProteinHuman cell lines and Mice Upregulated in HBV-associated HCC Diagnostic and PrognosticHBV-HCC vs normal p < 0.05Tissue27708241
2055TRIM32ProteinHumanUpregulated in HCC tumor tissues and HCC cell lines. Diagnostic and PrognosticHCC v/s Normal; significant predictor for the overall survival time of HCC patients and positively correlated with histological grade, tumor sizes of patients p < 0.05Tissue27573002
2058HIF1AProteinHumanUpregulated in at both an mRNA and protein level in patients with PLC Diagnostic and PrognosticCancer v/s Normal; predict survival of patients p < 0.05Tissue27173353
2059VEGFProteinHumanUpregulated in at both an mRNA and protein level in patients with PLC Diagnostic and PrognosticCancer v/s Normal; predict survival of patients p < 0.05Tissue27173353

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top